Literature DB >> 16465423

Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer.

Hajime Isomoto1, Akira Ohtsuru, Vera Braiden, Miyoko Iwamatsu, Fumio Miki, Yujo Kawashita, Yohei Mizuta, Yasufumi Kaneda, Shigeru Kohno, Shunichi Yamashita.   

Abstract

The prognosis of patients with metastatic gastric cancer, particularly peritoneal carcinomatosis, remains poor despite intensive interventions. Gene therapy and hyperthermia can be promising strategies for such advanced disease. The study was conducted to explore the possible effective therapeutic approach of suicide gene therapy with herpes simplex virus thymidine kinase (HSV-tk) in combination with hyperthermia for advanced gastric cancer. The heat shock protein (hsp) 70B gene promoter-oriented HSV-tk (HSP-tk)/ganciclovir (GCV) system directed by heat shock was developed. Hsp promoter activity under the control of heating was assessed by dual luciferase assay in gastric cancer cell lines and implanted tumors of nude mice. In vitro cytotoxic assay was performed using the HSP-tk/GCV delivered by the hemagglutinating virus of Japan (HVJ) liposome, with or without heating. Mice with subcutaneously xenografted tumors and peritoneal carcinomatosis were treated with hyperthermia and gene therapy using the HVJ-liposome-carrying HSP-tk. Assessment by luciferase assay demonstrated highly inducible and tumor-specific promoter activity in vitro and in vivo. Cytotoxic assays showed that cells transfected with HSP-tk became more sensitive to GCV with heating. A synergistic effect was also observed when treated with a non-heat-inducible cytomegalovirus (CMV) promoter-mediated HSV-tk/GCV and heating, indicating bystander killing. The HVJ-liposome-carrying HSP-tk/GCV combined with hyperthermia significantly inhibited the growth of subcutaneous tumors and prolonged survival of mice with peritoneal carcinomatosis. We conclude that the combination of suicide gene therapy with hyperthermia can provide a promising treatment modality for advanced gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465423

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol promotes angiogenesis in a mouse model.

Authors:  Young-Bin Chen; Ying-Wei Lan; Tsai-Hsien Hung; Lih-Geeng Chen; Kong-Bung Choo; Winston T K Cheng; Hsuan-Shu Lee; Kowit-Yu Chong
Journal:  Cell Stress Chaperones       Date:  2015-04-10       Impact factor: 3.667

2.  Egr1/HSP70 Promoter-Driven Activation of Gene Expression for Synergistic Anti-Hepatoma Using PEI-MZF Nanoparticles and Radiation.

Authors:  Jia Zhang; Min Dong; Yan Feng; Dongsheng Zhang; Mei Lin; Chenyan Yuan; Hongbo Li; Ling Wang; Hao Zhang; Chen Liang
Journal:  Int J Nanomedicine       Date:  2022-01-26

Review 3.  The changing face of gastric cancer: epidemiologic trends and advances in novel therapies.

Authors:  Raghav Chandra; Neeraja Balachandar; Sam Wang; Scott Reznik; Herbert Zeh; Matthew Porembka
Journal:  Cancer Gene Ther       Date:  2020-10-02       Impact factor: 5.987

4.  Construction of a novel vector expressing the fusion suicide gene yCDglyTK and hTERT-shRNA and its antitumor effects.

Authors:  Jia Li; Guiying Zhang; Ting Liu; Huan Gu; Lu Yan; Bolin Chen
Journal:  Exp Ther Med       Date:  2012-06-18       Impact factor: 2.447

5.  HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer.

Authors:  Yang Lifang; Tang Min; Ai Midan; Cao Ya
Journal:  J Exp Clin Cancer Res       Date:  2008-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.